EPCAM and lung cancer: Brocco et al. combined different biomarkers for tumor CSC-derived EVs and showed that the concentration of circulating tumor CSC–derived CD133+ CD326- EVs was higher in lung cancer patients than in healthy volunteers (Brocco et al., 2019).